These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 33803255)

  • 41. Gut Microbiome and Its Impact on Obesity and Obesity-Related Disorders.
    Sankararaman S; Noriega K; Velayuthan S; Sferra T; Martindale R
    Curr Gastroenterol Rep; 2023 Feb; 25(2):31-44. PubMed ID: 36469257
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Therapeutic advances in non-alcoholic fatty liver disease: A microbiota-centered view.
    Chen HT; Huang HL; Li YQ; Xu HM; Zhou YJ
    World J Gastroenterol; 2020 Apr; 26(16):1901-1911. PubMed ID: 32390701
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Gut Microbiota: An Important Player in Type 2 Diabetes Mellitus.
    Zhou Z; Sun B; Yu D; Zhu C
    Front Cell Infect Microbiol; 2022; 12():834485. PubMed ID: 35242721
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Advances in Understanding the Human Gut Microbiota and Its Implication in Pediatric Celiac Disease-A Narrative Review.
    Lupu VV; Trandafir LM; Raileanu AA; Mihai CM; Morariu ID; Starcea IM; Mocanu A; Butnariu LI; Stoleriu G; Salaru DL; Chisnoiu T; Munteanu D; Mitrofan C; Lupu A
    Nutrients; 2023 May; 15(11):. PubMed ID: 37299462
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The crucial role of early-life gut microbiota in the development of type 1 diabetes.
    Zhou H; Sun L; Zhang S; Zhao X; Gang X; Wang G
    Acta Diabetol; 2021 Mar; 58(3):249-265. PubMed ID: 32712802
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The Human Gut Microbiota.
    Harmsen HJ; de Goffau MC
    Adv Exp Med Biol; 2016; 902():95-108. PubMed ID: 27161353
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Role of intestinal microbiota and metabolites on gut homeostasis and human diseases.
    Lin L; Zhang J
    BMC Immunol; 2017 Jan; 18(1):2. PubMed ID: 28061847
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A New Approach to Polycystic Ovary Syndrome: The Gut Microbiota.
    Yurtdaş G; Akdevelioğlu Y
    J Am Coll Nutr; 2020; 39(4):371-382. PubMed ID: 31513473
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Current understanding of the role of gut dysbiosis in type 1 diabetes.
    Abdellatif AM; Sarvetnick NE
    J Diabetes; 2019 Aug; 11(8):632-644. PubMed ID: 30864231
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Microbiota medicine: towards clinical revolution.
    Gebrayel P; Nicco C; Al Khodor S; Bilinski J; Caselli E; Comelli EM; Egert M; Giaroni C; Karpinski TM; Loniewski I; Mulak A; Reygner J; Samczuk P; Serino M; Sikora M; Terranegra A; Ufnal M; Villeger R; Pichon C; Konturek P; Edeas M
    J Transl Med; 2022 Mar; 20(1):111. PubMed ID: 35255932
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Beneficial Effects of Dietary Polyphenols on Gut Microbiota and Strategies to Improve Delivery Efficiency.
    Kumar Singh A; Cabral C; Kumar R; Ganguly R; Kumar Rana H; Gupta A; Rosaria Lauro M; Carbone C; Reis F; Pandey AK
    Nutrients; 2019 Sep; 11(9):. PubMed ID: 31540270
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Gut dysbacteriosis and intestinal disease: mechanism and treatment.
    Meng X; Zhang G; Cao H; Yu D; Fang X; de Vos WM; Wu H
    J Appl Microbiol; 2020 Oct; 129(4):787-805. PubMed ID: 32277534
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Promises of microbiome-based therapies.
    Bajaj JS; Ng SC; Schnabl B
    J Hepatol; 2022 Jun; 76(6):1379-1391. PubMed ID: 35589257
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Application of Microbiome-Based Therapies in Chronic Respiratory Diseases.
    Lee SH; Lee JH; Lee SW
    J Microbiol; 2024 Mar; 62(3):201-216. PubMed ID: 38635003
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Bifidobacterium reduction is associated with high blood pressure in children with type 1 diabetes mellitus.
    Lakshmanan AP; Shatat IF; Zaidan S; Jacob S; Bangarusamy DK; Al-Abduljabbar S; Al-Khalaf F; Petroviski G; Terranegra A
    Biomed Pharmacother; 2021 Aug; 140():111736. PubMed ID: 34034069
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Therapeutic interventions for gut dysbiosis and related disorders in the elderly: antibiotics, probiotics or faecal microbiota transplantation?
    Vemuri RC; Gundamaraju R; Shinde T; Eri R
    Benef Microbes; 2017 Apr; 8(2):179-192. PubMed ID: 28008784
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Biome engineering-2020.
    Brüssow H
    Microb Biotechnol; 2016 Sep; 9(5):553-63. PubMed ID: 27471167
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Gut microbiota as the critical correlation of polycystic ovary syndrome and type 2 diabetes mellitus.
    Duan L; An X; Zhang Y; Jin D; Zhao S; Zhou R; Duan Y; Zhang Y; Liu X; Lian F
    Biomed Pharmacother; 2021 Oct; 142():112094. PubMed ID: 34449321
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The role of the gut microbiota in the treatment of inflammatory bowel diseases.
    Aggeletopoulou I; Konstantakis C; Assimakopoulos SF; Triantos C
    Microb Pathog; 2019 Dec; 137():103774. PubMed ID: 31586663
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The Effect of Microbiome-Modulating Agents (MMAs) on Type 1 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Zhang Y; Huang A; Li J; Munthali W; Cao S; Putri UMP; Yang L
    Nutrients; 2024 May; 16(11):. PubMed ID: 38892608
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.